Methods and compositions for cancer treatment
US-2024424094-A1 · Dec 26, 2024 · US
Combinations including ABX196 for the treatment of cancer
US11826372B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11826372-B2 |
| Application number | US-202117543247-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 6, 2021 |
| Priority date | Sep 14, 2016 |
| Publication date | Nov 28, 2023 |
| Grant date | Nov 28, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating cancer, comprising administration, in a patient in need thereof, of a therapeutically effective amount of an antitumor pharmaceutical combination free of antigens comprising: (i) a compound ABX196 of formula (I) and, (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent. 2. The method according to claim 1 , wherein the compound ABX196 of formula (I) (i) and the at least one chemotherapeutic agent and/or the at least one immunotherapeutic agent (ii) are administered separately. 3. The method according to claim 1 , wherein the compound ABX196 of formula (I) (i) and the at least one chemotherapeutic agent and/or the at least one immunotherapeutic agent (ii) are administered semi-simultaneously. 4. The method according to claim 1 , wherein the administrations of the compound ABX196 of formula (I) (i) and of the at least one chemotherapeutic agent and/or the at least one immunotherapeutic agent (ii) are spaced out over a period of time so as to obtain maximum efficacy of the combination. 5. The method according to claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of doxorubicin, cyclophosphamide, epirubicin, idarubicin, mitoxantrone and oxaliplatin. 6. The method according to claim 1 , wherein the chemotherapeutic agent is doxorubicin or sorafenib. 7. The method according to claim 1 , wherein the immunotherapeutic agent is an antibody specific of a tumor antigen selected from the group consisting of Her2/neu, EGFR, VEGF, CD20, CD52, CD33, TACE, cathepsin S, uPA, uPAR, PD-1, Glypican-3, claudin-3, claudin-4, BMCA and CTLA4. 8. The method according to claim 1 , wherein the immunotherapeutic agent is a monoclonal anti-PD1 antibody. 9. The method according to claim 1 , wherein the cancer is selected from the group consisting of melanoma, hepatocarcinoma, colorectal cancer and bladder cancer.
Assignees
Inventors
Classifications
Epidermal growth factor receptors [EGFR] · CPC title
Proteoglycans, e.g. glypican, brevican or CSPG4 · CPC title
Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4 · CPC title
Molecules with a "CD" designation not provided for elsewhere · CPC title
CD20 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11826372B2 cover?
- An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.
- Who is the assignee on this patent?
- Abivax
- What technology area does this patent fall under?
- Primary CPC classification A61K39/0011. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).